Biomea Fusion Crescita futura

Criteri Future verificati 0/6

Si prevede che gli utili di Biomea Fusion diminuiranno a 15% all'anno, mentre si prevede che i suoi ricavi annuali cresceranno a 68.9% all'anno. Si prevede che l'EPS diminuirà di 4.6% all'anno. Si prevede che il ritorno sul capitale proprio sarà -92.8% in 3 anni.

Informazioni chiave

-15.0%

Tasso di crescita degli utili

-4.59%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	25.2%
Tasso di crescita dei ricavi	68.9%
Rendimento futuro del capitale proprio	-92.75%
Copertura analitica	Good
Ultimo aggiornamento	14 May 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Seeking Alpha • Oct 07

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:BMEA - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2028	N/A	-105	-109	-128	3
12/31/2027	N/A	-107	-79	-78	7
12/31/2026	N/A	-63	-65	-65	7
3/31/2026	N/A	-45	-56	-56	N/A
12/31/2025	N/A	-62	-70	-70	N/A
9/30/2025	N/A	-96	-87	-86	N/A
6/30/2025	N/A	-112	-100	-100	N/A
3/31/2025	N/A	-129	-114	-114	N/A
12/31/2024	N/A	-138	-120	-120	N/A
9/30/2024	N/A	-144	-113	-113	N/A
6/30/2024	N/A	-140	-112	-111	N/A
3/31/2024	N/A	-127	-105	-105	N/A
12/31/2023	N/A	-117	-100	-97	N/A
9/30/2023	N/A	-108	-98	-94	N/A
6/30/2023	N/A	-102	-91	-87	N/A
3/31/2023	N/A	-95	-80	-76	N/A
12/31/2022	N/A	-82	-63	-62	N/A
9/30/2022	N/A	-71	-59	-58	N/A
6/30/2022	N/A	-61	-53	-50	N/A
3/31/2022	N/A	-52	-45	-41	N/A
12/31/2021	N/A	-42	-39	-35	N/A
9/30/2021	N/A	-30	-25	-22	N/A
6/30/2021	N/A	-19	-15	-14	N/A
3/31/2021	N/A	-11	-8	-8	N/A
12/31/2020	N/A	-5	-5	-4	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che BMEA rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che BMEA rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che BMEA rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che BMEA non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che BMEA non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che BMEA non sarà più redditizia tra 3 anni.

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/05/15 08:48
Prezzo dell'azione a fine giornata	2026/05/15 00:00
Utili	2026/03/31
Utili annuali	2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Biomea Fusion, Inc. è coperta da 15 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Naureen Quibria	Capital One Securities, Inc.
Yigal Nochomovitz	Citigroup Inc
Jonathan Wolleben	Citizens JMP Securities, LLC

Biomea Fusion Crescita futura

Criteri Future verificati 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 10% to US$7.17

Price target decreased by 27% to US$8.29

Price target decreased by 14% to US$20.00

Price target decreased by 13% to US$20.50

Price target decreased by 34% to US$28.11

Price target decreased by 17% to US$41.00

Recent updates

New minor risk - Market cap size

Biomea Fusion, Inc. Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Biomea Fusion, Inc., Annual General Meeting, Jun 10, 2026

Biomea Fusion, Inc. Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

New major risk - Financial position

Biomea Fusion Presents Phase II Covalent-111 Data In Type 2 Diabetes At 19th International Conference On Advanced Technologies And Treatments For Diabetes

Biomea Fusion, Inc. Presents Covid-111 Study Results At the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

Co-Founder recently bought US$55k worth of stock

Biomea Fusion, Inc. Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide At Obesityweek®? 2025

Price target decreased by 10% to US$7.17

Biomea Fusion, Inc. Announces Impairment Charges for the Three Months Ended September 30, 2025

Biomea Fusion, Inc. Announces First Patient Dosed in Phase I Study of BMF-650 A Next-Generation Oral GLP-1 Receptor Agonist

Biomea Fusion Announces Positive 52-Week Results from Phase II Covid-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

Biomea Fusion: Surging On Data, Sinking On Funding - I'm On The Sidelines

Biomea Fusion, Inc. has filed a Follow-on Equity Offering.

Biomea Fusion, Inc. Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model

Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?

Price target decreased by 27% to US$8.29

Biomea Fusion, Inc. Announces Board Changes

Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from Russell 2000 Index

Biomea Fusion, Inc. Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

New major risk - Shareholder dilution

Biomea Fusion, Inc. has filed a Follow-on Equity Offering.

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent Flt3 Inhibitor Bf-500 in Relapsed or Refractory Acute Leukemia At Eha 2025

New major risk - Share price stability

Price target decreased by 14% to US$20.00

Biomea Fusion, Inc. Selects for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

Price target decreased by 13% to US$20.50

Biomea Fusion, Inc., Annual General Meeting, Jun 11, 2025

Biomea Fusion, Inc. Auditor Raises 'Going Concern' Doubt

Biomea Fusion, Inc. Announces Chief Executive Officer Changes

Biomea Fusion Inc. Announces Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-Cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Price target decreased by 34% to US$28.11

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Biomea Fusion, Inc. Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Biomea Fusion, Inc. Presents the New Analysis from the Escalation Portion of COVALENT-111 at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

High number of new and inexperienced directors

Independent Director recently bought US$101k worth of stock

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Biomea Fusion, Inc. Announces FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

New major risk - Financial position

High number of new and inexperienced directors

CFO & Principal Accounting Officer recently bought US$55k worth of stock

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target decreased by 17% to US$41.00

Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical Hold

New major risk - Share price stability

Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Price target increased by 10% to US$54.43

Biomea Fusion, Inc., Annual General Meeting, Jun 12, 2024

Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)

Price target decreased by 9.2% to US$49.38

Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes

Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

New minor risk - Share price stability

Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

New major risk - Revenue and earnings growth

Biomea Fusion Announces Two Poster Presentations At Upcoming Ash Annual Meeting 2023

Biomea Fusion, Inc. Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)